News
OBSV
--
0.00%
--
Implied Volatility Surging for ObsEva (OBSV) Stock Options
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
Zacks · 13h ago
GME, LAC, AMC and COHR among premarket gainers
Tenax Therapeutics, Inc. (TENX) +70% after announcing acquisition of PH Precision Med.Aclaris Therapeutics (ACRS) +66% on positive data from mid-stage rheumatoid arthritis.Minerva Neurosciences (NERV) +42% on announcing sale of Seltorexant Royalty for up
Seekingalpha · 14h ago
5 Penny Stocks Riding The Biotech Wave In January 2021
Jan 19, 2021 (Penny Stocks via COMTEX) -- Biotech Penny Stocks To Watch This Week If you have been looking at the biotech industry, you've likely stumbled...
Penny Stocks · 16h ago
CRNT, AT, RIOT and GME among midday movers
Gainers: Ceragon Networks (CRNT) +67%.ObsEva (OBSV) +60%.Polar Power (POLA) +50%.Charah Solutions (CHRA) +46%.Avinger (AVGR) +45%.DBV Technologies (DBVT) +42%.Novan (NOVN) +42%.Senseonics (SENS) +42%.Atlantic Power (AT) +40%.Driven Brands (DRVN) +31%.Losers: Dogness (DOGZ) -22%.Cardiff Oncology (CRDF) -21%.SOS (SOS) -21%.Ur-Energy (URG) -15%.Cyclacel
Seekingalpha · 4d ago
OBSV Stock: 7 Things for ObsEva Investors to Know Before Investing in the Penny Stock
ObsEva (NASDAQ:OBSV) stock is soaring higher on Friday despite there not being any noteworthy news today. Source: Bukhta Yurii / Shutterstock.com To go along with the increase in price, shares of OBSV stock are also experiencing heavy trading today. That’s...
InvestorPlace · 4d ago
ObsEva, DBV Technologies leads healthcare gainers; Cardiff Oncology, SOS among major losers
Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%, Calithera Biosciences (CALA) -10%, Check-Cap (CHEK) -9%.
Seekingalpha · 4d ago
Mid-Morning Market Update: Markets Open Lower; JPMorgan Beats Q4 Estimates
Following the market opening Friday, the Dow traded down 0.96% to 30,693.81 while the NASDAQ fell 0.72% to 13,018.85. The S&P also fell, dropping 0.86% to 3,762.80.
Benzinga · 4d ago
Thinking about buying stock in Obseva SA, DBV Technologies, BlackBerry, Five Prime Therapeutics, or BioNano Genomics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OBSV, DBVT, BB, FPRX, and BNGO.
PR Newswire - PRF · 4d ago
ACB, APHA among premarket gainers
Charah Solutions (CHRA) +105% on being awarded large-scale, 12-Year ash marketing contract.DBV Technologies (DBVT) +57% on FDA response regarding Viaskin Peanut application.ObsEva (OBSV) +43%.Atlantic Power (AT) +41% on being acquired by I Squared
Seekingalpha · 4d ago
BB, LCI, OBSV and MIK among after-hours movers
Gainers: [[OBSV]] +33%. [[DBVT]] +28.1%. [[TUFN]] +21.8%. [[BB]] +17.2%. [[PPIH]] +13.4%.Losers: [[EAF]] -5%. [[MIK]] -4.4%. [[DOGZ]] -3.9%. [[WBAI]] -3.5%. [[LCI]] -3.2%.
Seekingalpha · 5d ago
3 Penny Stocks For Your Watch List In January 2021
Jan 14, 2021 (Penny Stocks via COMTEX) -- Trending Penny Stocks To Watch For The End Of The Week As we inch further into 2021, investors continue to focus on...
Penny Stocks · 5d ago
H.C. Wainwright Thinks ObsEva SA’s Stock is Going to Recover
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ObsEva SA (OBSV), with a price target of $17.00. The company's
SmarterAnalyst · 01/12 11:25
ObsEva stops US Phase 3 study with Yselty for endometriosis
ObsEva ([[OBSV]] -4.5%) has announced validation of European marketing application seeking approval for Yselty (linzagolix) for the Treatment of uterine fibroids.The Yselty Europe application is based on positive data from the
Seekingalpha · 01/11 19:25
ObsEva Provided Updates on Yselty Clinical Development Program
ObsEva SA (NASDAQ: OBSV) today announced several important updates on its Yselty program. Validation of Marketing Authorization Application for the Treatment of Uterine Fibroids
Benzinga · 01/11 10:47
ObsEva Provides Update on Yselty(R) (Linzagolix) Clinical Development Program
Globe Newswire · 01/11 06:00
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
\- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021\- Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expecte...
GlobeNewswire · 01/11 06:00
Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced the addition of Elizabeth Garner, M.D., M.P.H., to it...
GlobeNewswire · 01/07 15:00
ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 - 14, 2021
Globe Newswire · 01/07 06:00
ObsEva appoints David Renas as CFO; shares +6% Premarket
ObsEva SA (OBSV) appoints David Renas as Chief Financial Officer and member of the company’s Executive Committee. He will be based in the U.S.The move is effective today.David Renas has
Seekingalpha · 01/04 10:28
ObsEva appoints David Renas as Chief Financial Officer
Globe Newswire · 01/04 06:00
Webull provides a variety of real-time OBSV stock news. You can receive the latest news about Obseva through multiple platforms. This information may help you make smarter investment decisions.
About OBSV
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
More